Equity Overview
Price & Market Data
Price: $10.74
Daily Change: -$0.32 / 2.98%
Range: $10.51 - $12.53
Market Cap: $232,931,264
Volume: 13,780
Performance Metrics
1 Week: -9.06%
1 Month: 22.88%
3 Months: 7.29%
6 Months: -22.10%
1 Year: -22.10%
YTD: -24.95%
Company Details
Employees: 22
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.